Vaccine Adjuvants MarketPosted by Sanket Solanki on May 10th, 2019 Adjuvants are compounds that enhance the bodys immunogenic response against antigens. Hence, adjuvants are added to vaccines to increase their ability to induce long-term protection against infections. Vaccine adjuvants are in the process of development, and presently aluminum salts and MF59 are the only adjuvants found feasible for human use. R&D for potent vaccine adjuvants is progressing at a drastic rate after the development of new-generation vaccines. Modern-day vaccines are less immunogenic, thus resulting in the need for more powerful adjuvants for use in vaccines. This has to led to high investments by researchers and scientists to invest in R&D activities for safer and effective vaccine adjuvants, thus enhancing market growth. Factors driving the world vaccine adjuvants market are rising support of government in R&D, high prevalence of diseases, increasing focus on improved vaccines, and strategic developmental moves adopted by companies such as agreements, acquisitions, and collaborations. However, side effects of adjuvants and cost of adjuvant development restrict the market growth. Moreover, emerging markets are opening avenues of opportunities for the growth of this market. The market is segmented by product type, route of administration, disease type, application, and geography. On the basis of product type, it is divided into adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others. In terms of route of administration, it is classified into oral, intramuscular, intranasal, subcutaneous, intradermal, and others. On the basis of disease type, it is segmented into cancer, infectious diseases, and others. Furthermore, on the basis of application it is bifurcated into research and commercial applications. Geographically, the market is analyzed across Europe, North America, Asia-Pacific, and LAMEA. Major companies have conducted product launches, approvals, acquisitions, and collaborations for the development of novel vaccine adjuvants, thereby building a competitive landscape in the market. For instance, CSL Limited obtained approval for Seqirus flucelvax quadrivalent (Influenza Vaccine) from U.S. FDA, which provides protection against influenza virus A and B. Moreover, Agenus Inc. acquired PhosImmune Inc.; this acquisition helped Agenus in the development of new cancer vaccines as well as combination therapies. Download Sample Report @ https://www.alliedmarketresearch.com/request-toc-and-sample/1666 Key players operating in this market are CSL Corporate, Brenntag Biosector A/S, Agenus, Inc., Novavax, Inc., Spectrum Pharmaceuticals, Inc., SEPPIC, Inc., Invivogen, Avanti Polar Lipids, Inc., MPV Technologies, and OZ Biosciences. KEY MARKET BENEFITS:
KEY MARKET SEGMENTS: By Product Type
By Route of Administration
By Diseases
By Geography
About us Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain. Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client's insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm. Like it? Share it!More by this author |